Compare MLSS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | NSRX |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 38.9M |
| IPO Year | 1996 | 2024 |
| Metric | MLSS | NSRX |
|---|---|---|
| Price | $0.56 | $3.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 133.3K | 10.8K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $1.98 |
| 52 Week High | $0.68 | $9.99 |
| Indicator | MLSS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 73.26 | 52.47 |
| Support Level | $0.25 | $2.83 |
| Resistance Level | N/A | $3.60 |
| Average True Range (ATR) | 0.04 | 0.27 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 86.19 | 50.00 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.